



# CSL Limited

David Lamont  
Chief Financial Officer  
May 2018

---

## Legal Notice

### Forward looking statements

The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL. You can identify these forward looking statements by the fact that they use words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “may,” “assume,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestments; research collaborations; litigation or government investigations, and CSL’s ability to protect its patents and other intellectual property. The statements being made in this presentation do not constitute an offer to sell, or solicitation of an offer to buy, any securities of CSL.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by any person (including CSL). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based.

Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, CSL disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of CSL since the date of these materials.

### Trademarks

Except where otherwise noted, brand names designated by a <sup>TM</sup> or <sup>®</sup> throughout this presentation are trademarks either owned by and/or licensed to CSL or its affiliates.

# CSL – a Global Biotechnology Company

**30+**   
Countries  
Of operations around the world

**6.9+**  
US\$ Billion  
In annual revenue

**8**  
Manufacturing sites

 Australia  Switzerland  
 China  United Kingdom  
 Germany  United States

**20,000+**   
Employees around the world



**2.6**  
US\$ Billion  
In R&D investments in last 5 years  
advances exciting pipeline

**1,400+**   
R&D employees

**190+**   
Plasma collection centres across  
Europe and North America

# CSL Values

## **Patient Focus**

We deliver on  
our promise to  
patients

## **Innovation**

We turn  
innovative  
thinking into  
solutions

## **Integrity**

We walk the  
talk



## **Collaboration**

We are stronger  
together

## **Superior Performance**

We take pride in  
our results

# Shareholder Value



# Strategic Objectives



## Growth

Maximize portfolio value & deliver new product launches



## Efficiency

Be the most efficient, highest quality plasma player



## Influenza

Deliver on influenza strategy



## Innovation


Pursue new opportunities to diversify portfolio and enhance growth




## People & Culture

Create a culture that attracts, retains and develops the best talent

# Strong and Consistent Revenue Growth



# Group Sales – Global Reach






# Group Sales – Diverse Revenue Stream

CSL FY17  
Sales US\$6.7B

 **privigen®**

 **Hizentra®**



**Kcentra®**


**BERINERT®**

 **HAEGARDA®**


 **IDELVION®**

 **AFSTYLA®**

# CSL Behring Global Manufacturing Network




# Ruide JV - Presence in High Growth Market




- Acquisition of a majority stake in Chinese plasma fractionator Ruide in August 2017:
  - Modest entry point to key market
  - CSL Behring has operational control
- Plasma products market in China:
  - ~US\$3.3b in 2016
  - 5 year growth rate ~15%
- China is the fastest Ig growth market:
  - Second in volume to the US
  - Demand forecasted to outstrip supply
- Planning for plasma centre expansion

# Seqirus




# Seqirus


## Seasonal Influenza Sales Mix




# Capital Allocation – Last 10 Years



# Capital Expenditure




# Capital Expenditure





# Plasma Collection Network Expansion



## As of April 2018

- Collection centres 194
- Unmatched rate of centre openings
  - 2-3 per month

## Outlook

- ~25 to 30 centre openings in FY18
- CPL improves as more centres at peak efficiency
  - ~3 years from opening
- Replicating efficiencies in China over time

# Kankakee Facility

## Base Fractionation expansion



# Broadmeadows Facility

## Albumin & Immunoglobulins expansion



# Lengnau Facility


Recombinant therapies - greenfields



# Research & Development



# Research & Development



# Research & Development

## TRANSPLANT

- Emerging franchise
- High unmet need
- Leverages existing products
- Vitaeris collaboration


## CIDP

- Privigen® approved in US
- Hizentra® approved in US and EU

## OTHER DEVELOPMENTS


- Proprietary stem cell gene therapy platform - Calimmune acquisition
- CSL112 - Phase 3 study commencing 1H CY18
- CSL730 (Fc Multimer) – Phase 1 trial commenced

# Shareholder Returns






# Shareholder Returns



## Share Buybacks

- 24% earnings per share accretion
- WACC reduction



# Strong Platform to Deliver Sustainable Growth

- Market leader in US\$29b plasma protein industry
- Most efficient plasma collection network
- Broad portfolio of innovative products and global sales reach
- World class R&D capabilities
- 2<sup>nd</sup> largest manufacturer of influenza vaccines in US\$6b industry
- Strong balance sheet and cashflow

---

## CSL Limited

### Contact:

**Bernard Ronchi**

**Senior Manager, Investor  
Relations**

Ph: +61 3 9389 3470

E: [bernard.ronchi@csl.com.au](mailto:bernard.ronchi@csl.com.au)

ASX: CSL

[www.csl.com.au](http://www.csl.com.au)

